BREAKING NEWS
Lung Cancer Trial Results Show Mortality Benefit with Low-Dose CT
(UPDATE – November 4, 2010) NCI has released initial results from the National Lung Screening Trial (NLST), a randomized national trial involving more than 53,000 current and former heavy smokers ages 55 to 74. The trial compared the effects of two lung cancer screening procedures—low-dose helical computed tomography (CT) and standard chest X-ray—on lung cancer mortality and found 20 percent fewer lung cancer deaths among trial participants screened with low-dose helical CT. Read more >>
NEWS
Crizotinib Continues to Show Promise for Some Lung Tumors, Faces Challenge of Drug Resistance
New data from a phase I trial of crizotinib, a small-molecule drug that targets cancer-causing chromosomal rearrangements involving the gene ALK, in patients with non-small cell lung cancer (NSCLC) add to positive results presented earlier this year at the American Society of Clinical Oncology annual meeting. Read more > >
Pancreatic Cancers May Develop Slowly Over Many Years
Study suggests that screening could potentially detect the disease earlyCetuximab May Benefit Some Patients with KRAS Gene Mutations
Closer analysis shows that one type of mutation still responds to the drugProtein Found on Tumor Blood Vessels Might Be Cancer Target
Discovery has potential implications for tumor imaging and drug developmentMore Evidence Suggests Aspirin May Prevent Colorectal Cancer
Long-term data showed fewer cases and deaths in European aspirin takers
A MESSAGE TO READERS
Series Archives Now Available
Last year, the NCI Cancer Bulletin began publishing four new series of articles that focus on the topics of Survivorship, Technology, Communications, and Oncology Nursing. Each series featured an icon that identified the topic. Readers can access a full list of the articles in each series by clicking on the icon. Look for additional articles on these and other topics in the future.
IN DEPTH
Engineering Progress against a Rare Cancer
The Chordoma Foundation is trying to build networks of researchers who share information
Featured Clinical Trial: Targeted Antibody Therapy for Metastatic Adrenocortical Carcinoma
Will inhibiting IGF-1R improve progression-free survival?
Recognition of Animal Welfare in Biomedical Science Takes Center Stage
Researchers and advocates gathered last week to discuss animals in research
UPDATES
FDA Update
- Labeling Change Includes Warning for a Class of Prostate Cancer Drugs
- Dasatinib Approved as First-line Treatment for Chronic Myelogenous Leukemia
- Trastuzumab Becomes First Targeted Therapy Approved for Stomach Cancer
Notes
- In Memoriam: Joan Mauer, Chief of NCI’s Clinical Trials Monitoring Branch
- NCI to Co-host Scientific Journalism Workshop in Rio de Janeiro
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
